Merck (MRK) says WELIREG in combination with lenvatinib demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, one of the study's dual primary endpoints, for treatment of ccRCC

Merck & Co said WELIREG in combination with lenvatinib demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, one of the study's dual primary endpoints, reducing the risk of disease progression or death by 26% in patients with advanced ccRCC whose disease progressed on or after treatment with a PD-1 or PD-L1 inhibitor compared to cabozantinib. At the final analysis, overall survival, the study's other dual primary endpoint, did not meet statistical significance for patients who received WELIREG in combination with lenvatinib compared to cabozantinib.